Business
Magenta Therapeutics Announces Additional Preliminary Positive Results from Ongoing Phase 2 Clinical Trial of MGTA-145 and Plerixafor in Patients with Multiple Myeloma at the American Society of Clinical Oncology (ASCO) Annual Meeting
– Preliminary results from the initial cohort of 10 patients were previously reported on May 12 in a published abstract at the European Hematology
About this update from Dianthus Therapeutics, Inc.
[{"type":"text","content":"\n– Preliminary results from the initial cohort of 10 patients were previously reported on May 12 in a published abstract at the European Hematology Association (EHA) Congress –\n\n– The cumulative data as of the data cut-off date show that all patients (15/15) treated with MGTA-145 and plerixafor met the primary endpoint of sufficient stem cell mobilization and collection for transplant –\n\n– All patients (12/12) transplanted with MGTA-145 and plerixafor to date have successfully engrafted; six patients have completed day-100 follow up with demonstrated durable engraftment –\n\n– These results will also be presented at the EHA Congress, June 9-17, 2021 –\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\n\nMagenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced additional positive results from a Phase 2 clinical trial of MGTA-145 and plerixafor in patients with multiple myeloma at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually June 4-8, 2021.\n\n“We are very pleased to see continued favorable results for MGTA-145 and plerixafor for stem cell mobilization and collection in patients with multiple myeloma,” said Jason Gardner, D.Phil., President and Chief Executive Officer, Magenta Therapeutics. “These results build on those previously disclosed from this study and the Phase 1 trials to further demonstrate MGTA-145 and plerixafor’s potential as a rapid, reliable, well-tolerated approach to stem cell mobilization and collection, which has positive implications for patients and donors.”\n\nAdditional Results – MGTA-145 Multiple Myeloma Phase 2 Clinical Trial\n\nThe investigator-initiated, 25-patient Phase 2 clinical trial is designed to evaluate the ability of MGTA-145, in combination with plerixafor, to mobilize and collect hematopoietic stem cells for autologous stem cell transplant in patients with multiple myeloma. This study is led by Surbhi Sidana, M.D., Assistant Professor of Medicine in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University School of Medicine.\n\nPreviously reported results from this trial were announced on May 12, 2021, in a published abstract for the European Hematology Association (EHA) Congress and provide...